Sudhakar Reddy Chintharlapalli

Serving as a bridge between preclinical and clinical development, phase zero studies can de-risk drug development by unlocking crucial pharmacokinetic and biodistribution data to optimize radiopharmaceutical drug candidates. Patient-centricity is at the core of phase zero studies and ethical considerations must be front and center in decision-making.

• Join this discussion-based workshop to gain insights on:
• Uncovering variations in compassionate use across countries like South Africa, Australia, Germany, and India, each with unique purposes and ethical considerations
• Ensuring ethical practices in diagnostics trials and patient involvement, advocating against unnecessary patient risk
• Guiding the design of Phase 1 trials by providing insights into optimal dosing, scheduling, and safety considerations